Murine leukemia RL♂1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL)

Cancer Science

Volumn 94, Issue 11, 2003, Pages 931-936

  Uenaka, Akiko ^a   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD4 ANTIGEN; CELL PROTEIN; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN KINASE B; RETINOIC ACID; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

5' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BASE PAIRING; CANCER INHIBITION; CYTOSOL; CYTOTOXIC T LYMPHOCYTE; ENDOSOME; EXON; GENE LIBRARY; GENE OVEREXPRESSION; IMMUNIZATION; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOLECULAR CLONING; MOUSE; MOUSE STRAIN; MURINE LEUKEMIA; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SARCOMA; SPLEEN CELL; TUMOR GROWTH;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; HISTOCOMPATIBILITY ANTIGENS; LEUKEMIA; MICE; OLIGOPEPTIDES; SARCOMA, EXPERIMENTAL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0344237232     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01380.x     Document Type: Review

References (53)

1. Foley EJ. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res 1953; 13: 835-7.
2. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 1943; 3: 326-33.
3. Klein G, Sjögren HO, Klein E, Hellström KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960; 20: 1561-72.
4. Old LJ, Boyse EA, Clarke DA, Carswell EA. Antigenic properties of chemically induced tumors. Ann N Y Acad Sci 1962; 101: 80-106.
5. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957; 18: 769-78.
6. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991; 49: 281-355.
7. Melief CJM. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 1992; 58: 143-75.
8. Rosenberg AS, Mizuochi T, Sharrow SO, Singer A. Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med 1987; 165: 1296-315.
9. Singer A, Munitz TI, Golding H, Rosenberg AS, Mizuochi T. Recognition requirements for the activation, differentiation and function of T-helper cells specific for class I MHC alloantigens. Immunol Rev 1987; 98: 143-70.
10. Sato H, Boyse EA, Aoki T, Iritani C, Old LJ. Leukemia-associated transplantation antigens related to murine leukemia virus. The X.1 system: immune response controlled by a locus linked to H-2. J Exp Med 1973; 138: 593-606.
11. DeLeo AB, Shiku H, Takahashi T, John M, Old LJ. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus-related antigens and alloantigens on cultured fibroblasts and sarcoma cells: description of a unique antigen on BALB/c Meth A sarcoma. J Exp Med 1977; 146: 720-34.
12. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Deplaen E, Van der Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
13. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173: 1373-84.
14. Cox AL, Skipper JCA, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264: 716-9.
15. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumor-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369: 67-71.
16. Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E. Identification of a unique antigen peptide pRL1 on BALB/c RL♂1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J Exp Med 1994; 180: 1599-607.
17. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 161: 265-70.
18. Gnjatic S, Nagata Y, Jager E, Stockert E, Shankara S, Roberts BL, Mazzara GP, Lee SY, Dunbar PR, Dupont B, Cerundolo V, Ritter G, Chen YT, Knuth A, Old LJ. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000; 97: 10917-22.
19. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 11810-3.
20. Shastri N. Needles in haystacks: identifying specific peptide antigens for T cells. Curr Opin Immunol 1996; 8: 271-7.
21. Uenaka A, Hata H, Win S, Ono T, Wada H, Nakayama E. ELISPOT cloning of tumor antigens recognized by cytotoxic T-lymphocytes from a cDNA expression library. Cancer Immun 2001; 1: 8.
22. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-93.
23. Van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz E, Chapiro J, Van den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptide recognized by human T cells. Immunol Rev 2003; 188: 51-64.
24. Lethe B, van den Eynde B, van Pel A, Corradin G, Boon T. Mouse tumor rejection antigen P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992; 22: 2283-8.
25. Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453-7.
26. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185: 453-9.
27. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184: 2207-16.
28. Wölfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K-H, Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 1994; 24: 759-64.
29. Ikeda H, Ohta N, Furukawa K, Miyazaki H, Wang L, Kuribayashi K, Old LJ, Shiku H. Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcoma. Proc Natl Acad Sci USA. 1997; 94: 6375-9.
30. Wölfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269: 1281-4.
31. Mayrand SM, Green WR. Non-traditionally derived CTL epitopes: exceptions that prove the rules? Immunol Today 1998; 19: 551-6.
32. De Bergeyck V, De Plaen E, Chomez P, Boon T, Van Pel A. An intracisternal A-particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia. Eur J Immunol 1994; 24: 2203-12.
33. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM. The immunodominant major histocompatibility complex class-I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci USA 1996; 93: 9730-5.
34. Jaffiee EM, Pardoll DM. Murine tumor antigens: is it worth the search? Curr Opin Immunol 1996; 8: 622-7.
35. Manki A, Ono T, Uenaka A, Seino Y, Nakayama E. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res 1998; 58; 1960-4.
36. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 2001; 13: 625-32.
37. Nakayama E, Shiku H, Takahashi T, Oettgen HF, Old LJ. Definition of a unique cell surface antigen of mouse leukemia RL♂1 by cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1979; 76: 3486-90.
38. Keyaki A, Kuribayashi K, Sakaguchi S, Masuda T, Yamashita J, Handa H, Nakayama E. Effector mechanism of syngeneic anti-tumor responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukemia RL♂1 in the nude mouse system. Immunology 1985; 56: 141-51.
39. Nakayama E, Uenaka A. Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med 1985; 161: 345-55.
40. + cells in tumor rejection. Jpn J Cancer Res 1989; 80: 649-54.
41. Ono T, Uenaka A, Nakayama E. Production of murine leukemia RL♂1 rejection antigen peptide pRL1a by proteolysis of natural precursor pRL1b. Jpn J Cancer Res 1996; 87: 1165-70.
42. Wada H, Matsuo M, Uenaka A, Shimbara N, Shimizu K, Nakayama E. Rejection antigen peptides on BALB/c RL♂1 leukemia recognized by cytotoxic lymphocytes: derivation from the normally untranslated 5′ region of the Akt proto-oncogene activation by long terminal repeat. Cancer Res 1995; 55; 4780-3.
43. Tanino M, Matsuo, M, Uenaka A, Tsukuda K, Ouchida M, Nakayama E, Shimizu K. Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL♂1 cells. Mol Carcinog 1999; 26: 286-97.
44. Ota S, Ono T, Morita A, Uenaka A, Harada M, Nakayama E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen presenting cells. Cancer Res 2002; 62: 1471-6.
45. Matsuo M, Wada H, Honda S, Tawara I, Uenaka A, Kanematsu T, Nakayama E. Expression of multiple unique rejection antigens on murine leukemia BALB/c RL♂1 and the role of dominant Akt antigen for tumor escape. J Immunol 1999; 162: 6420-5.
46. 1 and allogeneic C57BL/6 mice. Int J Oncol 2002; 20: 1019-25.
47. + effector T cells. J Exp Med 1984; 54: 1295-311.
48. + regulatory T cells during the course of transplantable tumor growth and protection from 3-methylcholanthrene-induced tumorigenesis by CD25-depletion. Jpn J Cancer Res 2002; 93: 911-6.
49. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor) monoclonal antibody. Cancer Res 1999; 59: 3128-33.
50. Uenaka A, Hirano Y, Hata H, Sanda W, Aji T, Tanaka M, Ono T, Skipper JCA, Shimizu K, Nakayama E. Cryptic epitope on a murine sarcoma Meth A generated by exon extension as a novel mechanism. J Immunol 2003; 170: 4862-8.
51. Cheung WM, Chu AH, Chu PW, Ip NY. Cloning and expression of a novel nuclear matrix-associated protein that is regulated during the retinoic acid-induced neuronal differentiation. J Biol Chem 2001; 276: 17083-91.
52. Ono T, Sato S, Kimura N, Tanaka M, Shibuya A, Old LJ, Nakayama E. Serological analysis of BALB/c methylcholanthrene sarcoma Meth A by SEREX: identification of a cancer/testis antigen. Int J Cancer 2000; 88: 848-51.
53. Matsutake T, Srivastava PK. The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein. Proc Natl Acad Sci USA 2001; 98: 3992-7.